Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1-2 Study of Combination Therapy With INCMGA00012 (Anti-PD-1), INCAGN02385 (Anti-LAG-3), and INCAGN02390 (Anti-TIM-3) in Participants With Select Advanced Malignancies

NCT04370704 is registered in ClinicalTrials.gov with Incyte Corporation as lead sponsor.

NCT NCT04370704
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04370704 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1-2 Study of Combination Therapy With INCMGA00012 (Anti-PD-1), INCAGN02385 (Anti-LAG-3), and INCAGN02390 (Anti-TIM-3) in Participants With Select Advanced Malignancies
Lead sponsor
Incyte Corporation
Phase
Phase 1/2
Overall status
Completed
Start date
July 27, 2020
Completion date
August 25, 2025
Enrollment
61 (actual)
Sites
17

Conditions

As the registry lists them; a condition with its own page is linked.

melanoma